Sapient Capital LLC Sells 132 Shares of Elevance Health, Inc. (NYSE:ELV)

Sapient Capital LLC decreased its position in shares of Elevance Health, Inc. (NYSE:ELV) by 3.0% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 4,252 shares of the company’s stock after selling 132 shares during the period. Sapient Capital LLC’s holdings in Elevance Health were worth $2,211,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Professional Financial Advisors LLC bought a new position in Elevance Health in the 3rd quarter worth approximately $1,238,000. CHICAGO TRUST Co NA grew its position in shares of Elevance Health by 110.2% during the third quarter. CHICAGO TRUST Co NA now owns 1,667 shares of the company’s stock valued at $867,000 after purchasing an additional 874 shares in the last quarter. Exchange Traded Concepts LLC increased its holdings in shares of Elevance Health by 50.8% in the third quarter. Exchange Traded Concepts LLC now owns 1,970 shares of the company’s stock worth $1,024,000 after purchasing an additional 664 shares during the last quarter. Asio Capital LLC lifted its position in shares of Elevance Health by 2.4% in the third quarter. Asio Capital LLC now owns 9,689 shares of the company’s stock worth $5,038,000 after buying an additional 229 shares in the last quarter. Finally, FARMERS & MERCHANTS TRUST Co OF LONG BEACH bought a new position in Elevance Health during the third quarter valued at approximately $204,000. Hedge funds and other institutional investors own 89.24% of the company’s stock.

Elevance Health Trading Up 0.3 %

ELV stock traded up $1.26 during mid-day trading on Monday, reaching $503.14. The company had a trading volume of 44,163 shares, compared to its average volume of 1,015,448. The company has a market capitalization of $116.94 billion, a PE ratio of 18.97, a price-to-earnings-growth ratio of 1.08 and a beta of 0.82. The firm has a 50 day moving average of $531.94 and a 200 day moving average of $529.15. Elevance Health, Inc. has a 12 month low of $435.99 and a 12 month high of $567.26. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.49 and a quick ratio of 1.49.

Elevance Health (NYSE:ELV) last announced its quarterly earnings data on Wednesday, July 17th. The company reported $10.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $9.99 by $0.13. Elevance Health had a return on equity of 20.64% and a net margin of 3.89%. The company had revenue of $43.22 billion for the quarter, compared to analysts’ expectations of $42.99 billion. During the same quarter in the prior year, the firm earned $9.04 earnings per share. Elevance Health’s revenue was down .4% compared to the same quarter last year. On average, equities analysts predict that Elevance Health, Inc. will post 37.26 earnings per share for the current fiscal year.

Elevance Health Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, September 25th. Shareholders of record on Tuesday, September 10th were given a dividend of $1.63 per share. This represents a $6.52 dividend on an annualized basis and a yield of 1.30%. The ex-dividend date was Tuesday, September 10th. Elevance Health’s dividend payout ratio (DPR) is 24.64%.

Insider Transactions at Elevance Health

In related news, CEO Gail Boudreaux sold 34,000 shares of Elevance Health stock in a transaction that occurred on Monday, July 22nd. The shares were sold at an average price of $500.98, for a total transaction of $17,033,320.00. Following the transaction, the chief executive officer now directly owns 126,709 shares of the company’s stock, valued at $63,478,674.82. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. In other Elevance Health news, Director Robert L. Dixon, Jr. sold 305 shares of the stock in a transaction dated Friday, July 19th. The shares were sold at an average price of $506.76, for a total transaction of $154,561.80. Following the completion of the sale, the director now directly owns 9,721 shares of the company’s stock, valued at approximately $4,926,213.96. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Gail Boudreaux sold 34,000 shares of Elevance Health stock in a transaction that occurred on Monday, July 22nd. The stock was sold at an average price of $500.98, for a total transaction of $17,033,320.00. Following the completion of the transaction, the chief executive officer now directly owns 126,709 shares in the company, valued at approximately $63,478,674.82. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 35,058 shares of company stock valued at $17,588,116. Company insiders own 0.35% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the stock. TD Cowen decreased their price target on shares of Elevance Health from $624.00 to $589.00 and set a “buy” rating on the stock in a research note on Friday, July 19th. Morgan Stanley assumed coverage on Elevance Health in a research note on Monday, June 24th. They set an “overweight” rating and a $643.00 price objective on the stock. Stephens reaffirmed an “overweight” rating and issued a $615.00 price objective on shares of Elevance Health in a research note on Thursday, September 5th. Bank of America reissued a “neutral” rating and set a $530.00 target price (down previously from $646.00) on shares of Elevance Health in a research report on Thursday, July 18th. Finally, Barclays raised their price target on Elevance Health from $611.00 to $622.00 and gave the stock an “overweight” rating in a research report on Thursday. One analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $605.07.

Elevance Health Company Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.